Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant | Zendy

Amandine Le Bourgeois | Zendy; Marianne CosteBurel | Zendy; Thierry Guillaume | Zendy; Pierre Péterlin | Zendy; Alice Garnier | Zendy; Marie C. Béné | Zendy; Patrice Chevallier | Zendy

Open Access

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant

Author(s) -

Amandine Le Bourgeois,

Marianne CosteBurel,

Thierry Guillaume,

Pierre Péterlin,

Alice Garnier,

Marie C. Béné,

Patrice Chevallier

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2021.26344

Subject(s) - antibody response , haematopoiesis , hematopoietic stem cell transplantation , medicine , hematopoietic stem cell , messenger rna , antibody , stem cell , virology , immunology , transplantation , biology , genetics , gene

This cohort study examines safety and antibody responses after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant (HSCT).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research